Phase 2 Data: CBL-514 Cuts Visceral Fat Volume 12% vs Placebo Increase

CBL-514 is an injectable agent that selectively triggers apoptosis in adipocytes without affecting surrounding tissues. In the analyzed cohorts from trials CBL-0204 and CBL-0205, participants with BMI 22-30 received up to 600 mg injected into the lower abdomen every three weeks for 12 weeks. MRI quantified visceral fat at baseline, four weeks post-treatment, and eight-to-twelve weeks post-treatment. The design allowed dose titration based on fat thickness, producing a mean 10.45% VAT reduction at later follow-up versus an 11.76% increase on placebo. Most adverse events were mild, transient injection-site reactions.

Visceral fat drives insulin resistance and cardiometabolic risk more than subcutaneous depots. Current GLP-1 receptor agonists produce substantial weight loss but weight regain is common after discontinuation. Preclinical data indicated that pairing CBL-514 with tirzepatide yielded greater initial loss and slower regain once tirzepatide stopped, supporting the hypothesis that fewer remaining adipocytes limit lipid reaccumulation. Human confirmation of this mechanism remains pending larger studies.

The present findings derive from a small MRI subgroup (n=40) within phase 2 programs not yet published in peer-reviewed form. Next steps require phase 3 trials with primary endpoints of sustained weight maintenance at 52 weeks after GLP-1 cessation, plus cardiovascular outcome data to establish clinical benefit beyond fat-volume change.